← All trials
NCT06644794
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2024
- Primary completion
- Sep 10, 2026
- Completion date
- Dec 1, 2027
- First posted
- Oct 16, 2024
- Last posted
- Oct 16, 2024
- Enrollment
- 336
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shandong University of Traditional Chinese MedicineLead sponsor
- Shandong University of Traditional Chinese MedicineSponsor investigator
- Shandong University of Traditional Chinese MedicineOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.